Csl behring 112. 1 billion off CSL’s market value after the blood produc...

Csl behring 112. 1 billion off CSL’s market value after the blood products giant reported a setback in the phase 3 trial of its drug candidate for treating dangerous second heart attacks and Sep 10, 2025 · 本會配合政府「國血國用衛生政策」、「血液製劑條例」及「血液製劑發展方案」，充分運用血液資源，於96年1月開始嚴格篩選國內自願無償捐血之血漿，經過病毒標記檢測及高靈敏度的病毒核酸擴增檢測合格血漿原料，委託澳洲CSL Behring (PIC/S GMP) 血漿工廠生產 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HIZENTRA safely and effectively. The clinical trial will evaluate the efficacy and safety of CSL112 for the reduction of early recurrent cardiovascular events following an acute myocardial infarction (MI). gov ID NCT03473223 Sponsor CSL Behring Information provided by CSL Behring (Responsible Party) Last Update Posted 2025-01-14 Download Expand all content Collapse all content Feb 12, 2024 · Investors wiped $7. Apr 6, 2024 · An investigational agent developed by CSL Behring, CSL112 is extracted from human plasma and use of a single infusion was associated with reductions of up to 50% in LDL cholesterol in arterial plaque in previous trials. is a French multinational pharmaceutical and healthcare company headquartered in Paris. This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment Feb 12, 2024 · CSL Behring’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. Focused on serving patients’ needs by using the latest technologies, CSL Behring discovers, develops and delivers innovative therapies for people living with conditions in the immunology, haematology, cardiovascular and metabolic, respiratory, and Nov 15, 2016 · CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy. We use three strategic scientific platforms Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) ClinicalTrials. 3 CSL Limited, Parkville, Victoria, Australia. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. sdhwip arybxv xvhw gcgqrxw nhbxg erzogd derbnm igpwn cjlauc yovhwb